NCT01660750 - A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

December 31, 2015

Conditions

Multiple Myeloma

Interventions

DRUG

Carfilzomib

IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days

DRUG

Cyclophosphamide

PO on days 1, 8, and 15 every 28 days

DRUG

Dexamethasone

40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.

Trial Locations (5)

Duke University Medical Center, Durham

Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles

Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs

Fred Hutchinson Cancer Research Center, Seattle

University of Massachusettes Memorial, Worcester